When everyone was making quick money by making "generic drugs", she chose a slower and more difficult path. Zhong Huijuan has spent thirty years proving that shortcuts create businessmen, while difficult roads create creators. --- In the 1990s, the main theme of China's pharmaceutical industry was "imitation", which was a "shortcut" with low risk and quick results. However, Zhong Huijuan, who had abundant industry resources and her husband was already an industry giant, made a decision that was puzzling to everyone: she gave up her stable teaching job and the convenience of resources at her fingertips, and started from scratch to devote herself to the research and development of "innovative drugs" that was the longest, most arduous, and had the highest failure rate at the time. 1. The origin: an abandoned "pass" In 1995, for most people, Zhong Huijuan held a "golden pass" in life. On the one hand, there is a stable and decent career as a chemistry teacher, without having to face market storms; on the other hand, there is the mature platform and deep resources that her husband, Sun Piaoyang, has built in the pharmaceutical industry. Relying on either side, she can easily achieve success and stability in the worldly sense. However, this "pass" that countless people dream of has become an "instruction manual" that needs to be broken in her hands. She is clearly aware that the "success" that comes with dependence cannot fill her inner desire for "self-creation," nor can it fill a country's industry gap that is "stuck" in the field of severe medication. True independence begins with being wary of "shortcuts." 2. Prescription: Prescribe "innovative" prescriptions at the feast of "imitation". Resigned from teaching position and joined the start-up Hansoh Pharmaceuticals (the predecessor of Hansoh Pharmaceuticals).
Zhong Huijuan
Asian Cover Figure | Zhong Huijuan: At the Door of "Shortcuts," She Chose the "Hardest" Prescription
Asian Cover Figure · Vision
Issue No. 051-
[Summary]
When everyone was making generic drugs for quick money, she chose a slower, harder path. Zhong Huijuan proved over thirty years: shortcuts make merchants; the hard road makes creators.
In the 1990s, the dominant theme of China's pharmaceutical industry was "copying" — a low-risk, fast-return shortcut. Yet Zhong Huijuan, who held substantial industry resources and whose husband was already a titan of the sector, made a decision that baffled everyone: she gave up a stable teaching career, abandoned readily available resource advantages, and started from scratch in innovative drug R&D — the longest, most grueling, highest-failure-rate path in the industry.
I. Origin: A "Golden Pass" Left Behind
In 1995, Zhong Huijuan held what most would consider a golden ticket in life.
On one side, a stable and respected career as a chemistry teacher, safe from market turbulence; on the other, the mature platform and deep resources her husband Sun Piaoyang had already built in the pharmaceutical industry. Leaning on either would have easily delivered conventional success and security.
Yet this pass that countless people dreamed of became, in her hands, a "user manual" she needed to escape. She recognized clearly that success built on dependence could not fill her inner craving for self-creation, nor could it address a nation's critical gap in severe-disease medication.
True independence begins with vigilance against shortcuts.
II. The Prescription: Writing "Innovation" Amid a Feast of "Generics"
Resigning from teaching and joining the fledgling Hansoh Pharmaceutical (predecessor of Hansoh Pharma), Zhong Huijuan faced an industry landscape that was almost barren. At the time, the mainstream strategy for domestic pharma was "generic manufacturing" — copying expired-patent drugs from overseas, bringing them to market quickly, and earning reliable profits. It was a safe and bustling feast.
"Innovative drugs"? Investment typically ran into billions, timelines spanned decades, failure was the norm, and success was the exception. Against capital and time, this was tantamount to a "poison" prescription.
But she insisted on writing this hardest of prescriptions. She did not charge ahead recklessly; instead, with the meticulousness of a science student, she devised a gradual "generic-innovation hybrid" strategy: first establishing a foothold with high-end generics, building a quality system aligned with international standards, then channeling every yuan of profit as "fuel" into the innovative drug pipeline aimed at the future.
In an industry chasing immediate returns, she chose to quietly prepare medicine for results a decade away.
III. Endurance: Measuring the "Marathon" of New Drugs with a Scientist's "Ruler"
Innovative drug R&D is a "Long March" without gunfire but equally brutal. From molecular screening, animal trials, through Phase I, II, and III clinical trials, every step is fraught with "cliff edges." Behind one successful drug stand ninety-nine silent failures and billions in capital evaporated.
Zhong Huijuan brought her chemistry teacher's rigor into the laboratory. She maintained an almost obsessive demand for data integrity, with production process standards precise to the finest degree. Through those long, quiet nights of R&D, her "ruler" measured not short-term financial statement gains, but cell experiment data curves, patient response rates, and whether drugs could truly address unmet medical needs.
Others gambled on probability with capital; she bet on scientific inevitability with expertise and patience.
IV. The Effect: When a "Lone Formula" Became a "Cornerstone"
Time is the ultimate reagent that tests all "long-termism." Nearly thirty years of perseverance and investment have begun to reveal the "therapeutic effect" of what was once a dismissed "lone formula" — one that is reshaping the competitive landscape.
Hansoh Pharma built a robust R&D pipeline across four core areas: oncology, central nervous system, anti-infection, and metabolic diseases. Multiple self-developed innovative drugs reached market, effectively breaking foreign giants' technology and market monopolies in severe-disease medication, giving Chinese patients access to affordable, high-quality domestic innovative drugs.
That hardest of prescriptions ultimately cured not just one company, but a clinical "wasteland" long neglected.
V. Independence: The Most Sophisticated "Combination Formula"
Through cycles of volume-based procurement shocks and capital tides in the pharmaceutical industry, Zhong Huijuan demonstrated remarkable strategic resolve. She did not diversify, did not speculate, and focused all resources on her core business of new drug R&D. In 2019, Hansoh Pharma successfully listed on the Hong Kong Stock Exchange, becoming an innovative pharmaceutical company with substantial proprietary intellectual property and a global outlook.
She and her husband Sun Piaoyang, who leads Hengrui Medicine, form a unique sight in China's pharmaceutical industry: a power couple running two giants, on complementary tracks, each independent, engaging the market through product strength and technical capability rather than traffic and stories.
Zhong Huijuan spent half her life illuminating the core pharmacology of one "combination formula": the power of women, the power of enterprises, the power of industry — their most effective ingredient has always been "independence."
She spent thirty years personally delivering that hardest prescription into the hands of the era. Shortcuts make clever merchants; the hard road makes great creators.
Her story is like a "sobriety dose" for a restless era. It challenges every individual and organization facing a choice: when a flower-lined "shortcut" with clear directions lies before you, do you still have the courage, for values and destinations your heart believes in, to resolutely walk toward that less-traveled, harder — yet potentially far broader — path?
